Fatal Interstitial Lung Disease after Addition of Sorafenib to a Patient with Lung Adenocarcinoma Who Had Failed to Improve with Erlotinib Alone

Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine kinase inhibitors has been extensively documented with decreasing incidence after appropriate patient selection due to increasing awareness over the years. However, ILD induced by sorafenib was mentioned with lower...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Yin, Meng, Jing, Zhao, Hong, Hu, Yi, Yan, Xiang, Zhao, Shao-Hong, Jiao, Shun-Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: April, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036133/
https://www.ncbi.nlm.nih.gov/pubmed/24926256
http://dx.doi.org/10.1159/000362402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036133/
https://www.ncbi.nlm.nih.gov/pubmed/24926256
http://dx.doi.org/10.1159/000362402

Ejemplares similares